1. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study 
Prof George Lau, MD, Yves Benhamou, MD, Prof Guofeng Chen, MD, Prof Jin Li, MD, Prof Qing Shao, MD, Dong Ji, MD, Fan Li, MD, Bing Li, MD, Jialiang Liu, MD, Prof Jinlin Hou, MD, Prof Jian Sun, MD, Cheng Wang, MD, Jing Chen, PhD, Vanessa Wu, BSc, April Wong, BSc, Chris L P Wong, PhD, Stella T Y Tsang, PhD, Yudong Wang, PhD, Leda Bassit, PhD, Sijia Tao, PhD, Yong Jiang, PhD, Hui- Mien Hsiao, MS, Ruian Ke, PhD, Alan S Perelson, PhD, Prof Raymond F Schinazi, PhD 
The Lancet Gastroenterology & Hepatology 
Volume 1, Issue 2, Pages (October 2016)
DOI: /S (16)
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Figure 1 Trial profile uRVR=ultrarapid virological response.
The Lancet Gastroenterology & Hepatology 2016 1, DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

3. Figure 2 Decline in mean hepatitis C viral load
Solid lines are mean model trajectories calculated from predicted viral load (see appendix p 9). Dashed horizontal line indicates the assay lower limit of quantification.
The Lancet Gastroenterology & Hepatology 2016 1, DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions